Matching articles for "Penbraya"
Penmenvy — A Second Pentavalent Meningococcal Vaccine
The Medical Letter on Drugs and Therapeutics • April 14, 2025; (Issue 1726)
The FDA has licensed the pentavalent vaccine
Penmenvy (GSK) for prevention of invasive
meningococcal disease caused by Neisseria
meningitidis serogroups A, B, C, W, or Y (MenABCWY)
in persons 10-25 years...
The FDA has licensed the pentavalent vaccine
Penmenvy (GSK) for prevention of invasive
meningococcal disease caused by Neisseria
meningitidis serogroups A, B, C, W, or Y (MenABCWY)
in persons 10-25 years old. Penmenvy is the second
pentavalent meningococcal vaccine to become
available in the US; Penbraya was licensed in 2023.
Penbraya: A Pentavalent Meningococcal Vaccine
The Medical Letter on Drugs and Therapeutics • March 18, 2024; (Issue 1698)
The FDA has licensed Penbraya (Pfizer), a pentavalent
polysaccharide conjugate meningococcal
vaccine, for prevention of invasive meningococcal
disease caused by Neisseria meningitidis
serogroups A, B, C, W,...
The FDA has licensed Penbraya (Pfizer), a pentavalent
polysaccharide conjugate meningococcal
vaccine, for prevention of invasive meningococcal
disease caused by Neisseria meningitidis
serogroups A, B, C, W, or Y (MenABCWY) in persons
10-25 years old. Penbraya is the only meningococcal
vaccine that contains all five of these serogroups.
Two quadrivalent polysaccharide conjugate
meningococcal vaccines containing serogroups A,
C, W, and Y (MenACWY; Menveo, MenQuadfi) and
two meningococcal serogroup B vaccines (MenB;
Bexsero, Trumenba) are available in the US (see
Table 2).